Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/52453
Full metadata record
DC FieldValueLanguage
dc.contributor.authorConnolly E.-
dc.contributor.authorWhite M.-
dc.contributor.authorSiva S.-
dc.contributor.authorBressel M.-
dc.contributor.authorTan J.-
dc.contributor.authorByrne K.-
dc.contributor.authorDay D.-
dc.contributor.authorMcCartney A.-
dc.contributor.authorWebber K.-
dc.contributor.authorDavid S.P.-
dc.date.accessioned2024-09-16T05:41:57Z-
dc.date.available2024-09-16T05:41:57Z-
dc.date.copyright2024-
dc.date.issued2024-09-02en
dc.identifier.citationInternational Journal of Radiation Oncology Biology Physics. Conference: 2024 ASTRO Annual Meeting. Walter E. Washington Convention Center, Washington United States. 120(2 Supplement) (pp e304), 2024. Date of Publication: 01 Oct 2024.-
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/52453-
dc.description.abstractPurpose/Objective(s): The AVATAR I Trial demonstrated that oligoprogressive luminal (ER positive, HER2 negative) advanced breast cancer patients undergoing established first-line systemic therapy for metastatic disease benefited from SRT as second-line therapy along with their original systemic treatment. A modified PFS, defined as a disease progression not amenable to SRT treatment, was reported as 10.4 months. Given this result, this trial in progress seeks to assess if SRT combined with systemic therapy CDK4/6 inhibitor and Aromatase Inhibitor (CDK4/6+AI) can improve the Quality of Life (QoL) for this cohort of patients. Materials/Methods: AVATAR II is a Phase 2 randomized control trial that enrolls patients with advanced luminal breast cancer who have received first-line systemic treatment in the metastatic setting with a CDK4/6+AI. Patients require at least 1 extracranial oligoprogressing lesion amenable to SRT. Patients who had chemotherapy for metastatic disease, leptomeningeal disease, or prior radiotherapy to an oligoprogressing lesion were excluded. Patients were randomized to Arm A; SRT to all oligoprogressing lesions and continue CDK4/6+AI systemic therapy or Arm B; no SRT and review to assess if a change in systemic therapy is required. If a patient subsequently progresses, further SRT was permitted to delay a change in systemic therapy in patients who had received SRT as part of the trial. At 3-monthly reviews, patient reported outcomes are measured using the EORTC QLQ C30 and FACT-B forms. The trial is expected to recruit 74 patients. The primary endpoint is the area under the curve (AUC) of the Quality of Life/Global Health Status score from the EORTC QLQ-C30 from baseline to the 12-month follow-up visit. The secondary endpoints are to determine Progression-free Survival (PFS) and PFS 2, defined as the time from randomization to the date of first and second evidence of progression, respectively. Other secondary endpoints include ST-PFS, defined as randomization to the first evidence of progression requiring change in systemic therapy, Overall Survival, treatment-related toxicity and further QoL assessment using AUC of the FACT-B Total score from baseline to 12 months. Result(s): TBD. Conclusion(s): Assessing quality of life (QoL) is integral to evaluating the overall impact of cancer treatment. AVATAR II aims to demonstrate that by delaying a change in systemic therapy and potentially more potent side effects, receiving SRT at this stage in a patient's treatment paradigm will have a more positive impact on patients' QoL.Copyright © 2024-
dc.publisherElsevier Inc.-
dc.relation.ispartofInternational Journal of Radiation Oncology Biology Physics-
dc.subject.meshbreast cancer-
dc.subject.meshradiotherapy-
dc.titleStereotactic radiotherapy (SRT) with maintenance systemic therapy vs. standard-of-care (SOC) systemic therapy for oligoprogressive ER-positive, HER2-negative breast cancer (AVATAR-II).-
dc.typeConference Abstract-
dc.identifier.affiliationOncology-
dc.description.conferencename2024 ASTRO Annual Meeting-
dc.description.conferencelocationWalter E. Washington Convention Center, Washington, United States-
dc.type.studyortrialObservational study (cohort, case-control, cross sectional, or survey)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1016/j.ijrobp.2024.07.674-
local.date.conferencestart2024-09-29-
dc.identifier.institution(Connolly, Siva, Tan, Byrne, David) Peter MacCallum Cancer Centre, Melbourne, VIC, Australia-
dc.identifier.institution(White, Day, McCartney, Webber) Department of Oncology, Monash Health, Melbourne, VIC, Australia-
dc.identifier.institution(Bressel) Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia-
local.date.conferenceend2024-10-02-
dc.identifier.affiliationmh(White, Day, McCartney, Webber) Department of Oncology, Monash Health, Melbourne, VIC, Australia-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeConference Abstract-
crisitem.author.deptOncology-
crisitem.author.deptOncology-
crisitem.author.deptOncology-
Appears in Collections:Conferences
Show simple item record

Page view(s)

70
checked on Mar 15, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.